Janus Henderson Group
ITOS

Janus Henderson Group’s iTeos Therapeutics ITOS Stock Holding History

Janus Henderson Group’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-500,324
Closed -$5.48M – 2576
2023
Q3 		$5.48M Buy
+500,324
New +$6.4M ﹤0.01% 798
2023
Q2 		– Sell
-72,246
Closed -$983K – 2639
2023
Q1 		$983K Buy
72,246
+27,586
+62% +$494K ﹤0.01% 1640
2022
Q4 		$872K Sell
44,660
-51,648
-54% -$1.01M ﹤0.01% 1430
2022
Q3 		$1.84M Buy
96,308
+47,850
+99% +$1.1M ﹤0.01% 1342
2022
Q2 		$998K Buy
+48,458
New +$1.15M ﹤0.01% 1327
2021
Q3 		– Sell
-1,056,545
Closed -$27.1M – 2210
2021
Q2 		$27.1M Sell
1,056,545
-116,663
-10% -$2.78M 0.01% 721
2021
Q1 		$40.1M Sell
1,173,208
-814,922
-41% -$29.4M 0.02% 607
2020
Q4 		$64.7M Buy
1,988,130
+988,298
+99% +$26.2M 0.03% 476
2020
Q3 		$24.7M Buy
+999,832
New +$26.9M 0.01% 654

Other funds holding ITOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group's ITOS Position: Q4 2023 in Review

Janus Henderson Group sold out of iTeos Therapeutics (ITOS) in Q4 2023, closing a stake of 500,324 shares — an estimated $5.48M sold.

Janus Henderson Group first reported a position in ITOS in Q3 2020 and held it in 9 quarters. The position peaked at $64.7M in Q4 2020. 137 funds tracked by Wall St. Rank hold ITOS as of Q4 2023.

  • Janus Henderson Group reported no remaining iTeos Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Janus Henderson Group sold 500,324 iTeos Therapeutics shares in Q4 2023, an estimated $5.48M.
  • Janus Henderson Group first reported a position in iTeos Therapeutics in Q3 2020 and held it in 9 quarters.
  • Janus Henderson Group's iTeos Therapeutics position peaked at $64.7M in Q4 2020.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2023.

Based on Janus Henderson Group's 13F filing for Q4 2023, filed 14 Feb 2024.